Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunogenicity and Safety Following In-House Recombinant Hepatitis B (Bio Farma) Vaccine Compared to Registered Hepatitis B Vaccine in Indonesian Population (Phase III)

NCT05482295 is registered in ClinicalTrials.gov with PT Bio Farma as lead sponsor.

NCT NCT05482295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05482295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunogenicity and Safety Following In-House Recombinant Hepatitis B (Bio Farma) Vaccine Compared to Registered Hepatitis B Vaccine in Indonesian Population (Phase III)
Lead sponsor
PT Bio Farma
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 30, 2025
Completion date
May 31, 2026
Enrollment
540 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

vaccine adverse reaction, vaccine reaction